Press release

Twist Bioscience and SOPHiA GENETICS Collaborate to Offer Optimized Genomic Solutions

Sponsored by Businesswire

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with SOPHiA GENETICS, leader in Data-Driven Medicine to bring access to the universal SOPHiA Platform for advanced genomic analysis to Twist’s customers, providing the analysis and interpretation of sequencing information. Together, the technologies will allow a customer to go from sample to interpretation of the results quickly and efficiently.

Sequencing the whole genome is expensive and often does not provide the depth of information needed for individual genes and the role they play in complex diseases. Target enrichment enables genomic sequencing efforts to be focused in specific regions of interest, which reduces cost and analysis time. Genomic solutions that combine Twist NGS enrichment solutions along with the SOPHiA AI-powered Platform for advanced DNA analysis are designed to support the implementation of NGS application for somatic and germline testing.

“SOPHiA’s mission is to democratize access to Data-Driven Medicine all around the world. With the addition of SOPHiA’s technology to Twist’s advanced products, clinical researchers will benefit from end-to-end, highly-accurate and reliable genomic solutions,” commented Jurgi Camblong CEO and Co-founder of SOPHiA GENETICS. “The combined solution will ultimately help experts precisely detect and characterize genomic mutations and use that information to improve outcomes.”

“Genomics research is enabling a shift from broad-based “one-size-fits-all” approach to a personalized experience,” commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “Pairing our industry-leading, rapidly customizable enrichment efficiency with SOPHiA’s robust analytical platform provides customers an important solution to achieve clinically actionable data while saving on sequencing costs. We are excited to work with SOPHiA to provide this new combined offering to clinical researchers around the world.”

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube


SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to improve health outcomes and economics worldwide. By unlocking the power of new-generation health data for cancer and rare diseases management, the universal SOPHiA Platform allows clinical researchers to act with precision and confidence. The company’s innovative approach enables an ever-expanding community of over 1,000 institutions to benefit from knowledge sharing, fostering a new era in healthcare. SOPHiA’s achievement is recognized by the MIT Technology Review’s “50 Smartest Companies”. More info: SOPHiAGENETICS.COM, follow @SOPHiAGENETICS on Twitter.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation Twist’s reach to potential new customers as a result of the collaboration, and the ability for Twist’s products to help customers achieve clinically actionable data while saving costs, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 10, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.